MCID: CLS016
MIFTS: 52

Clostridium Difficile Colitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Clostridium Difficile Colitis

MalaCards integrated aliases for Clostridium Difficile Colitis:

Name: Clostridium Difficile Colitis 12 56 15 74
Pseudomembranous Colitis 12 74
Enterocolitis, Pseudomembranous 45
Clostridium Difficile Infection 74
Pseudomembranous Enterocolitis 17
Colitis Pseudomembranous 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0060185
MeSH 45 D004761
NCIt 51 C128347
SNOMED-CT 69 51180003
ICD10 34 A04.7

Summaries for Clostridium Difficile Colitis

CDC : 3 Clostridioides difficile [klos–TRID–e–OY-dees dif–uh–SEEL] is a germ (bacteria) that causes life-threatening diarrhea. It is usually a side-effect of taking antibiotics.

MalaCards based summary : Clostridium Difficile Colitis, also known as pseudomembranous colitis, is related to toxic megacolon and microscopic colitis, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Clostridium Difficile Colitis is LTF (Lactotransferrin), and among its related pathways/superpathways are Prolactin Signaling Pathway and Defensins. The drugs Vancomycin and Piperacillin have been mentioned in the context of this disorder. Affiliated tissues include colon, kidney and spinal cord.

Disease Ontology : 12 A colitis characterized by an overgrowth of Clostridium difficile bacteria.

Related Diseases for Clostridium Difficile Colitis

Diseases related to Clostridium Difficile Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 toxic megacolon 31.1 ATP12A ATP4A
2 microscopic colitis 30.2 ATP12A ATP4A
3 gastrointestinal system disease 29.7 ATP12A ATP4A IL1B LTF
4 chemical colitis 11.6
5 colitis 11.3
6 megacolon 10.5
7 diarrhea 10.5
8 arthritis 10.4
9 cystic fibrosis 10.4
10 reactive arthritis 10.4
11 ulcerative colitis 10.4
12 haemophilus influenzae 10.3 IL1B LTF
13 hemolytic-uremic syndrome 10.3
14 peptic ulcer disease 10.3 ATP4A IL1B
15 fungal esophagitis 10.2 ATP12A ATP4A
16 diclofenac allergy 10.2 ATP12A ATP4A
17 gastroduodenal crohn's disease 10.2 ATP12A ATP4A
18 neonatal candidiasis 10.2 ATP12A ATP4A
19 photoallergic dermatitis 10.2 ATP12A ATP4A
20 squamous papillomatosis 10.2 ATP12A ATP4A
21 aspiration pneumonitis 10.2 ATP12A ATP4A
22 gastrointestinal neuroendocrine benign tumor 10.2 ATP12A ATP4A
23 gastric antral vascular ectasia 10.2 ATP12A ATP4A
24 granulomatous gastritis 10.2 ATP12A ATP4A
25 esophageal candidiasis 10.2 ATP12A ATP4A
26 gastric neuroendocrine neoplasm 10.2 ATP12A ATP4A
27 acute laryngitis 10.2 ATP12A ATP4A
28 duodenitis 10.2 ATP12A ATP4A
29 rumination disorder 10.2 ATP12A ATP4A
30 active peptic ulcer disease 10.2 ATP12A ATP4A
31 ovarian cancer 10.2
32 enterocolitis 10.2
33 leukemia 10.2
34 spinal cord injury 10.2
35 foodborne botulism 10.2
36 infant botulism 10.2
37 lymphoma 10.2
38 ischemic colitis 10.2
39 pneumonia 10.2
40 peritonitis 10.2
41 appendicitis 10.2
42 cytomegalovirus infection 10.2
43 congenital disorder of deglycosylation 10.2 ATP12A ATP4A
44 bladder calculus 10.2 ATP12A ATP4A
45 ischemic neuropathy 10.2 ATP12A ATP4A
46 bile reflux 10.2 ATP12A ATP4A
47 capillary disease 10.2 ATP12A ATP4A
48 dyskinesia of esophagus 10.2 ATP12A ATP4A
49 hernia, hiatus 10.2 ATP12A ATP4A
50 anismus 10.2 ATP12A ATP4A

Graphical network of the top 20 diseases related to Clostridium Difficile Colitis:



Diseases related to Clostridium Difficile Colitis

Symptoms & Phenotypes for Clostridium Difficile Colitis

UMLS symptoms related to Clostridium Difficile Colitis:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

Drugs & Therapeutics for Clostridium Difficile Colitis

Drugs for Clostridium Difficile Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1404-90-6 14969 441141
2
Piperacillin Approved Phase 4 66258-76-2 43672
3
Tazobactam Approved Phase 4,Not Applicable 89786-04-9 123630
4
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130 64778
5
Ceftazidime Approved Phase 4,Phase 2,Phase 3,Not Applicable 72558-82-8, 78439-06-2 5481173
6
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
7
Fidaxomicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 873857-62-6
8
Metronidazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 443-48-1 4173
9
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3 80621-81-4 46783403 6436173
10
Pantoprazole Approved Phase 4,Phase 3,Not Applicable 102625-70-7 4679
11
Cefazolin Approved Phase 4,Phase 2,Phase 3,Not Applicable 25953-19-9 33255 656510
12
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
13
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
14
Fosfomycin Approved Phase 4 23155-02-4 446987
15
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
16
leucovorin Approved Phase 4,Not Applicable 58-05-9 143 6006
17
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
18
Ceftriaxone Approved Phase 4,Phase 3,Phase 2 73384-59-5 5479530 5361919
19
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
20
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
21
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415 5280454
22
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
23
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
24
Titanium dioxide Approved Phase 4 13463-67-7
25
Loperamide Approved Phase 4,Phase 2,Phase 3 53179-11-6 3955
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Polyethylene glycol 3350 Phase 4,Phase 2,Phase 3,Not Applicable
32 Cathartics Phase 4,Phase 2,Phase 3,Not Applicable
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Laxatives Phase 4,Phase 2,Phase 3,Not Applicable
35 Piperacillin, Tazobactam Drug Combination Phase 4
36 beta-Lactamase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
37 beta-Lactams Phase 4
38 Antitubercular Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
39 penicillins Phase 4,Phase 3,Phase 2,Not Applicable
40 Lactams Phase 4
41 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Not Applicable
42 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Not Applicable
43 Fluoroquinolones Phase 4,Phase 3,Not Applicable
44 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 1,Not Applicable
45 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Proton Pump Inhibitors Phase 4,Phase 3,Phase 1,Not Applicable
48 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
49 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
50 Clindamycin palmitate Phase 4

Interventional clinical trials:

(show top 50) (show all 303)
# Name Status NCT ID Phase Drugs
1 Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection Unknown status NCT02237859 Phase 4 Vancomycin
2 Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
3 Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
4 Ciprofloxacin for Prevention of BK Infection Unknown status NCT01789203 Phase 4 Ciprofloxacin;placebo
5 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics Completed NCT02951702 Phase 4 Vancomycin Oral
6 Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
7 Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin Completed NCT01818141 Phase 4 Vancomycin;Fidaxomicin
8 A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population Completed NCT02254967 Phase 4 Fidaxomicin;Vancomycin
9 Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea Completed NCT01670149 Phase 4 Rifaximin;Placebo
10 Stress Ulcer Prophylaxis in the Intensive Care Unit Completed NCT02467621 Phase 4 Pantoprazole
11 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4 Cefadroxil discontinued early;Cefadroxil until drain removal
12 Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients Completed NCT03235947 Phase 4 Fosfomycin disodium;Trimethoprim / Sulfamethoxazole;Intravenous placebo
13 Screening to Prophylax Against Clostridium Difficile Infection - Recruiting NCT02996487 Phase 4 Vancomycin
14 A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections Recruiting NCT02692651 Phase 4 Fidaxomicin;Vancomycin
15 Optimal Treatment for Recurrent Clostridium Difficile Recruiting NCT02667418 Phase 4 Fidaxomicin;Vancomycin with Taper/Pulse;Vancomycin
16 C. Difficile and Ursodiol Recruiting NCT02748616 Phase 4 Ursodiol
17 Standardized Fecal Microbiota Transplantation for Crohn&Apos;s Diseases Recruiting NCT01793831 Phase 4
18 Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia Recruiting NCT03514446 Phase 4 Antibiotic therapy duration for 7 days
19 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
20 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO Recruiting NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
21 GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial Recruiting NCT03506113 Phase 4 Gram stain-guided antibiotic choice;Guidelines-based antibiotics choice
22 Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial Recruiting NCT02462590 Phase 4 L. rhamnosus GG - Probiotic;Placebo - Microcrystalline Cellulose
23 Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics Enrolling by invitation NCT03466502 Phase 4 Oral Vancomycin
24 Oral Vancomycin for Preventing Clostridium Difficile Recurrence Enrolling by invitation NCT03200093 Phase 4 Oral Vancomycin;Placebo
25 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment Enrolling by invitation NCT03388268 Phase 4 Oral Vancomycin;Placebo
26 Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection Not yet recruiting NCT03880539 Phase 4 bezlotoxumab;Vancomycin Oral
27 Treatment of Clostridium Difficile in Colonized Patients in the Hematology Oncology Population Not yet recruiting NCT03030248 Phase 4 Vancomycin Oral Capsule;Placebo Oral Capsule
28 Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery. Not yet recruiting NCT03756454 Phase 4
29 Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics. Not yet recruiting NCT03937999 Phase 4 Bezlotoxumab
30 Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy Suspended NCT00591357 Phase 4 loperamide;placebo
31 Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea Terminated NCT01972932 Phase 4
32 Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
33 A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System Terminated NCT01775397 Phase 4 Fidaxomicin;Vancomycin;Placebo
34 Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients Terminated NCT02200328 Phase 4 Metronidazole;Placebo
35 Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection Withdrawn NCT02464306 Phase 4 fidaxomicin
36 Use of Bismuth Subsalicylate in Clostridium Difficile Colitis Withdrawn NCT03592082 Phase 4 Bismuth Subsalicylate;standard antibiotic therapy
37 Fidaxomicin to Prevent Clostridium Difficile Colonization Withdrawn NCT01552668 Phase 4 Fidaxomicin;Placebo
38 Addition of Lactobacillus to Metronidazole in Treatment of CDAD Withdrawn NCT00304863 Phase 4 Lactobacillus GG
39 Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae Withdrawn NCT01543347 Phase 4 Temocillin
40 Transplantation of Fecal Microbiota for Clostridium Difficile Infection Unknown status NCT01958463 Phase 3
41 Randomized Controlled Trial Comparing Long and Short Duration of Antibiotic Prophylaxis for Patients Undergoing Sinus Lift Surgery Unknown status NCT02764710 Phase 3 Amoxicillin-Potassium Clavulanate Combination
42 Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant Unknown status NCT01817075 Phase 3 Chlorhexidine Gluconate
43 A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) Completed NCT01241552 Phase 3 SOC
44 A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) Completed NCT01513239 Phase 3 SOC
45 Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection Completed NCT00304356 Phase 3 Nitazoxanide
46 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea Completed NCT01983683 Phase 3 Cadazolid;Vancomycin;Cadazolid-matching placebo;Vancomycin-matching placebo
47 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea Completed NCT01987895 Phase 3 Cadazolid;Vancomycin;Cadazolid-matching placebo;Vancomycin-matching placebo
48 A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) Completed NCT01598311 Phase 3 CB-183,315;Vancomycin;Placebo
49 Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) Completed NCT01597505 Phase 3 Surotomycin;Vancomycin;Placebo
50 Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children Completed NCT01295918 Phase 3

Search NIH Clinical Center for Clostridium Difficile Colitis

Cochrane evidence based reviews: enterocolitis, pseudomembranous

Genetic Tests for Clostridium Difficile Colitis

Anatomical Context for Clostridium Difficile Colitis

MalaCards organs/tissues related to Clostridium Difficile Colitis:

42
Colon, Kidney, Spinal Cord, Bone, Liver, Lung, Breast

Publications for Clostridium Difficile Colitis

Articles related to Clostridium Difficile Colitis:

(show top 50) (show all 907)
# Title Authors Year
1
A Prospective Program to Reduce the Clinical Incidence of Clostridium difficile Colitis Infection after Cystectomy. ( 30218764 )
2019
2
Fidaxomicin and Fecal Microbiota Transplants for Severe Clostridium difficile Colitis. ( 30601771 )
2019
3
Trends in Incidence and Outcomes of Clostridium difficile Colitis in Hospitalized Patients of Febrile Neutropenia: A Nationwide Analysis. ( 30614941 )
2019
4
Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response. ( 30622186 )
2019
5
Clostridium difficile Colitis Prevention and Treatment. ( 30689174 )
2019
6
Prolonged non-operative management of clostridium difficile colitis is associated with increased mortality, complications, and cost. ( 30709552 )
2019
7
Clostridium difficile colitis in patients undergoing surgery for hip fractures: an analysis of 17,474 patients. ( 30799640 )
2019
8
Development of a Standardized Scoring System to Assess a Murine Model of Clostridium difficile Colitis. ( 30892111 )
2019
9
Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study. ( 30907672 )
2019
10
Constitutive STAT5 activation regulates Paneth and Paneth-like cells to control Clostridium difficile colitis. ( 30948494 )
2019
11
Community-acquired pseudomembranous colitis precipitated by loperamide. ( 31101326 )
2019
12
Combination of oral vancomycin and intra-colonic vancomycin: Successful treatment of complicated pseudomembranous colitis in a child patient. ( 30911393 )
2019
13
Incidence, Risk Factors, and Impact of Clostridium difficile Colitis Following Primary Total Hip and Knee Arthroplasty. ( 28870746 )
2018
14
Incidence, Risk Factors, and Impact of Clostridium difficile Colitis After Spine Surgery: An Analysis of a National Database. ( 28953711 )
2018
15
A case report of successful management of clostridium difficile colitis with antegrade Fidaxomicin through a mucous fistula obviating the need for subtotal colectomy. ( 29227855 )
2018
16
Risk Factors and Costs Associated With Clostridium difficile Colitis in Patients With Prosthetic Joint Infection Undergoing Revision Total Hip Arthroplasty. ( 29273290 )
2018
17
Editor's Spotlight/Take 5: How Common-and How Serious-Is Clostridium difficile Colitis After Geriatric Hip Fracture? Findings from the NSQIP Dataset. ( 29443838 )
2018
18
How Common-and How Serious- Is Clostridium difficile Colitis After Geriatric Hip Fracture? Findings from the NSQIP Dataset. ( 29443839 )
2018
19
Treatment of recurrent Clostridium difficile colitis: a narrative review. ( 29479439 )
2018
20
Prolonged antibiotic use leading to Clostridium difficile colitis in an ill returned traveller with acute fascioliasis. ( 29608740 )
2018
21
Reducing Clostridium difficile Colitis Rates Via Cost-Saving Diagnostic Stewardship. ( 29611494 )
2018
22
Clostridium difficile Colitis Leading to Reactive Arthritis: A Rare Complication Associated With a Common Disease. ( 29623279 )
2018
23
Frailty Predicts Morbidity and Mortality after Colectomy for Clostridium difficile Colitis. ( 29966560 )
2018
24
Clostridium difficile colitis complicating Kawasaki disease in children: Two case reports. ( 29977558 )
2018
25
Clostridium difficile colitis and zoonotic origins-a narrative review. ( 30151199 )
2018
26
A Case of Concomitant Emphysematous Cystitis and Clostridium difficile Colitis with Pneumoperitoneum. ( 30181931 )
2018
27
No survival advantage exists for patients undergoing loop ileostomy for clostridium difficile colitis. ( 30266417 )
2018
28
Infant progressive colonic stenosis caused by antibiotic-related Clostridium difficile colitis - a case report and literature review. ( 30301467 )
2018
29
Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review. ( 30521856 )
2018
30
Clostridium difficile colitis in the setting of subacute thyroiditis: the chicken or the egg. ( 30567894 )
2018
31
Clostridium difficile Colitis in a Patient With Abdominal Distention, Pain, and Severe Constipation. ( 30766366 )
2018
32
Apoptosis of intestinal epithelial cells restricts Clostridium difficile infection in a model of pseudomembranous colitis. ( 30451870 )
2018
33
Paediatric Clostridium difficile pseudomembranous colitis: a complication of refractory constipation? ( 29444797 )
2018
34
Pseudomembranous colitis in acute lymphoblastic leukaemia. ( 29500180 )
2018
35
Pseudomembranous colitis presenting as a mechanical large bowel obstruction. ( 27457536 )
2018
36
Acute Appendicitis: An Extracolonic Manifestation of Clostridium difficile Colitis. ( 28757875 )
2017
37
Protein-losing pseudomembranous colitis with cap polyposis-like features. ( 28522919 )
2017
38
IVIG - A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal microbiota transplants and fidaxomicin. ( 28331803 )
2017
39
Can Procalcitonin Contribute to the Diagnosis of Clostridium difficile Colitis? ( 28513121 )
2017
40
Serum-Derived Bovine Immunoglobulin as Novel Adjunct in Complicated Clostridium difficile Colitis Treatment. ( 28516109 )
2017
41
Effects of a New Hospital-Wide Surgical Consultation Protocol in Patients with Clostridium difficile Colitis. ( 28557651 )
2017
42
Clostridium Difficile, Colitis, and Colonoscopy: Pediatric Perspective. ( 28707191 )
2017
43
Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis. ( 28739791 )
2017
44
Polyethylene glycol intestinal lavage in addition to usual antibiotic treatment for severe Clostridium difficile colitis: a randomised controlled pilot study. ( 28760801 )
2017
45
Differentiating Clostridium difficile Colitis from Clostridium difficile Colonization in Ulcerative Colitis: A Role for Procalcitonin. ( 29032373 )
2017
46
A Curiously Rare Case of Septic Shock From Clostridium difficile Colitis. ( 26221790 )
2017
47
Identification of Signet Ring Cell Change in Colonic Subserosa in the Setting of Clostridium difficile Colitis. ( 27562801 )
2017
48
Vesicoileal fistula and Clostridium difficile colitis in a child with acute lymphoblastic leukemia. ( 27842209 )
2017
49
Successful Therapy of Severe Pseudomembranous Clostridium difficile Colitis Using a Combination of Fecal Microbiota Therapy and Fidaxomicin. ( 27978522 )
2017
50
Clostridium difficile colitis: A clinical review. ( 28131326 )
2017

Variations for Clostridium Difficile Colitis

Expression for Clostridium Difficile Colitis

Search GEO for disease gene expression data for Clostridium Difficile Colitis.

Pathways for Clostridium Difficile Colitis

Pathways related to Clostridium Difficile Colitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.58 CDC42 IL1B LEPR
2
Show member pathways
11.15 CCR6 DEFA4 LTF
3 10.84 CDC42 CLASP2

GO Terms for Clostridium Difficile Colitis

Cellular components related to Clostridium Difficile Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.8 CDC42 IL1B LTF

Biological processes related to Clostridium Difficile Colitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 antimicrobial humoral response GO:0019730 9.57 DEFA4 LTF
2 killing of cells of other organism GO:0031640 9.55 DEFA4 LTF
3 potassium ion import across plasma membrane GO:1990573 9.54 ATP12A ATP4A
4 establishment or maintenance of cell polarity GO:0007163 9.52 CDC42 CLASP2
5 antibacterial humoral response GO:0019731 9.51 DEFA4 LTF
6 positive regulation of epithelial cell migration GO:0010634 9.49 CCR6 CLASP2
7 ATP hydrolysis coupled proton transport GO:0015991 9.48 ATP12A ATP4A
8 innate immune response in mucosa GO:0002227 9.43 DEFA4 LTF
9 cellular sodium ion homeostasis GO:0006883 9.4 ATP12A ATP4A
10 macrophage differentiation GO:0030225 9.37 CDC42 PARP1
11 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.32 ATP12A ATP4A
12 positive regulation of neuron apoptotic process GO:0043525 9.26 CDC42
13 cellular potassium ion homeostasis GO:0030007 9.26 ATP12A ATP4A
14 response to gamma radiation GO:0010332 9.16 PARP1
15 sodium ion export across plasma membrane GO:0036376 9.16 ATP12A ATP4A
16 membrane disruption in other organism GO:0051673 8.96 DEFA4 LTF
17 antifungal humoral response GO:0019732 8.62 DEFA4 LTF

Molecular functions related to Clostridium Difficile Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
2 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Clostridium Difficile Colitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....